Dr Reddys launches Bortezomib for Injection 3.5 mg in US market

27 Jul 2022 , 01:53 PM

Dr. Reddys Laboratories announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade? (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA). The Velcade? Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health. Dr. Reddys Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.Powered by Capital Market – Live News